Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE: 600645)
Health Care · Biotechnology · CN
CN¥19.10
+2.25% today · -22.0% 1Y
Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE: 600645) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.30B and employs 1,935 people.
Over the last twelve months the share price has lost 22.0%, trading between 16.24 and 32.99.
Tweenvest scores Vcanbio Cell & Gene Engineering Corp., Ltd across four factors: quality 80/100, value 60/100, growth 26/100. Its strongest factor is quality.
600645 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.30B
- Revenue (TTM)
- $205.80M
- P/E
- 76.32
- EPS
- 0.25
- Dividend yield
- —
- Beta (5Y)
- -0.10
- 52-week high
- CN¥32.99
- 52-week low
- CN¥16.24
- Avg volume (3M)
- —
- Shares outstanding
- 455.90M
- Employees
- 1,935
- Next earnings
- —
About Vcanbio Cell & Gene Engineering Corp., Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, established in 1992 and headquartered in Tianjin, China, primarily focuses on providing cell preparation and cryopreservation services across the People's Republic of China. The company's offerings include the handling and storage of a diverse array of stem cells, such as hematopoietic stem cells derived from umbilical cord blood, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells, alongside immune cells. Beyond its core cell banking operations, Vcanbio delivers a spectrum of genetic testing services. These include non-invasive prenatal screening, pharmacogenomic testing for safe medication guidance in both adults and children, and analyses for disease genetics and susceptibility. Additionally, the company supplies essential raw materials for in vitro diagnostics, specifically monoclonal and polyclonal antibodies. Vcanbio is also actively involved in the research, development, manufacturing, and commercialization of various biological products, including genes, proteins, and antibodies, as well as pharmaceutical intermediates, experimental synthetic agents, in vitro diagnostic reagents, and medical devices.
- ISIN
- CNE000000545
- Founded
- 1992
- Listed since
- May 4, 1993
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Everest Medicines LimitedSEHK: 1952 | $1.33B | HK$29.60 | +3.35% |
| Ascentage Pharma Group InternationalSEHK: 6855 | $1.32B | HK$28.22 | -3.36% |
| Damora Therapeutics, Inc.NasdaqCM: DMRA | $1.30B | $20.22 | -4.08% |
| Liaoning Chengda Biotechnology Co., Ltd.SHSE: 688739 | $1.30B | CN¥21.20 | +0.86% |
| Vitrolife AB (publ)OM: VITR | $1.29B | Skr95.20 | -0.42% |
| Seegene, Inc.KOSDAQ: A096530 | $1.29B | ₩38,150.00 | +3.39% |
| Replimune Group, Inc.NasdaqGS: REPL | $1.26B | $13.07 | -2.65% |
| Daan Gene Co., Ltd.SZSE: 002030 | $1.26B | CN¥6.03 | +4.87% |
Figures last refreshed Oct 11, 2026.